Bosutinib price list in 2024

Bosutinib, a targeted therapy drug for chronic myelogenous leukemia, inhibits the growth and spread of cancer cells by inhibiting the activity of specific tyrosine kinases. However, as of 2024, bosutinib has not yet been approved by the China Food and Drug Administration for marketing. Therefore, if patients need to use it, they need to purchase it from overseas pharmacies.

There are multiple versions of bosutinib on overseas markets, including original drugs and generic drugs. These versions are guaranteed in terms of drug quality, but prices vary depending on the version and strength.

Original drugs mainly include Turkish and European versions. The European version of bosutinib has won wide recognition for its high quality and excellent efficacy, but it is relatively expensive. Specifically, the European version of bosutinib, which is 500mg*28 tablets, can cost tens of thousands of yuan per box, which has put financial pressure on some patients. In comparison, the price of the Turkish version of bosutinib is slightly more affordable, with the price of several thousand yuan per box making it affordable for more patients.

In addition to the original drug, there are also generic drugs of bosutinib on the Indian market. The version produced by India's Mylan company is relatively cheaper. The price of a box of 400mg*30 tablets is only more than 1,000 yuan per box. This price advantage makes generic drugs the first choice for many patients.

It should be noted that there are many risks involved in purchasing drugs overseas. It is recommended that patients carefully understand the drug information of different versions and specifications before purchasing, and choose regular channels to purchase to ensure the quality and safety of the drug.

In short,The price of bosutinib in overseas markets in 2024 will vary depending on different versions and specifications. Patients can choose the appropriate version and specifications according to their own needs and economic conditions.